• Philosophy
  • About
  • Portfolio
  • News
Contact

Investing in

breakthrough technologies

PHILOSOPHY

Investing in our beliefs of a technology— enabled world

Identifying opportunity and investing in the potential of growth and progress is at the heart of our investment approach.
Focusing on later-stage, pre-IPO financing rounds, our investments aim to capture the sweet spot of turning risk to reward.

ABOUT

Investing in a better future

At Korify, we invest in our vision of a better future. Enabling people to live up to their fullest potential is at the core of our strategy.
We do this by investing in some of the most groundbreaking ideas across multiple sectors.

Portfolio

News

News

Alto Neuroscience emerges from stealth

Alto is bringing EEG-based and AI-identified biomarkers to psychiatry to develop precision medicine for the brain.

Rejuveron Life Sciences will acquire majority shareholding in Rejuvenate Biomed

The funding is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).

Wonder Brands-picks up 20m - aims to build marketplace of latin american-e-commerce brands

Wonder Brands closed on $20 million in seed funding, co-led by ALLVP and Mountain Nazca, with participation from CoVenture, Victory Park Capital, GFC, QED (Fontes), Korify Capital, and Endeavor Catalyst.

atai x Revixia Life Sciences

atai Life Sciences announced the launch of Revixia Life Sciences, a wholly owned subsidiary developing Salvinorin A to treat a variety of mental health disorders.

atai x InnarisBio Inc.

atai Life Sciences and UniQuest, Australia’s leading university technology transfer company commercializing the research of The University of Queensland (UQ), today announced the launch of InnarisBio Inc. (InnarisBio), to develop a novel sol-gel intranasal drug delivery technology.

Bullish SPAC Merger

Crypto exchange Bullish will merge with SPAC Far Peak Acquisition Corporation and list on the NYSE by the end of the year, per Business Wire.

Update Recognify Life Sciences

Recognify Life Sciences to Commence Phase 2a Study in Cognitive Impairment Associated with Schizophrenia.

Update Perception Neuroscience <> Otsuka Pharmaceutical

Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders.

Korify Capital - LinkedIN

Korify Capital invests in breakthrough technologies.

CONTACT

If you are interested in learning more about Korify Capital, let us know.

I am a
© 2021 Korify Capital AG
Privacy Policy